RIVER EDGE, N.J., May 11, 2011 /PRNewswire/ -- Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced that on May 10, 2011 the Company received approval from the Therapeutic Products Directorate of Health Canada, the Canadian health regulatory agency, to market its Dual Stage Ultrafilters (DSU) in Canada to filter out biological contaminants from water and bicarbonate solution used in hemodialysis procedures.
"Nephros is pleased to have received approval from the Therapeutic Products Directorate to market its Dual Stage Ultrafilters in Canada," said Dr. Paul Mieyal, Acting CEO of Nephros, Inc. "Recent data have shown that the Nephros DSU, when used as part of the water purification system for dialysis systems, may reduce the required dosage of erythropoietin stimulating agents, which we believe will provide a unique benefit to patients. We are proud to have the opportunity to introduce this important product to dialysis patients in Canada."
According to the Canadian Organ Replacement Registry (CORR), in 2009 there were approximately 38,000 patients with End-Stage Renal Disease in Canada.
About Dual Stage Ultrafilters
The Nephros DSU is an FDA cleared device for the filtration of biological contaminants from water and bicarbonate concentrate used in hemodialysis procedures. Within the U.S., there are approximately 4,500 clinics providing over 50 million dialysis treatments to 350,000 patients annually. To perform hemodialysis, ultrapure water is crucial to the production of dialysate. Dialysis clinics have water purification systems; however, microbial contaminants can originate from the water treatment system, the water distribution loop, or the dialysate concentrates. The Nephros DSU f
|SOURCE Nephros, Inc.|
Copyright©2010 PR Newswire.
All rights reserved